Onesource Specialty Pharma Ltd (ONESOURCE) Q4FY26 Management Mirror - Mar-2026 Qtr
Long-Term Revenue & Margins
In the Mar'26 Qtr, management reaffirmed its Mar'28 organic revenue guidance of $400 million with ~40% EBITDA margins ($160 million), adding a medium-term target to build toward 50%+ Return on Capital (RoCE). This outlook remained consistent from the Sep'25 Qtr and Dec'25 Qtr, with the Dec'25 Qtr noting that the Mar'27 exit run rate would reflect near-close Mar'28 targets. [Status: Reaffirmed]
4 more themes on the ELITE plan.